Tags

Type your tag names separated by a space and hit enter

Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel.
Sci Rep 2019; 9(1):14913SR

Abstract

MicroRNA-210-3p is the most prominent hypoxia regulated microRNA, and it has been found significantly overexpressed in different human cancers. We performed the expression analysis of miR-210-3p in a retrospective cohort of breast cancer patients with a median follow-up of 76 months (n = 283). An association between higher levels of miR-210-3p and risk of disease progression (HR: 2.13, 95%CI: 1.33-3.39, P = 0.002) was found in the subgroup of patients treated with Epirubicin and Cyclophosphamide followed by Docetaxel. Moreover, a cut off value of 20.966 established by ROC curve analyses allowed to discriminate patients who developed distant metastases with an accuracy of 85% at 3- (AUC: 0.870, 95%CI: 0.690-1.000) and 83% at 5-years follow up (AUC: 0.832, 95%CI: 0.656-1.000). Whereas the accuracy in discriminating patients who died for the disease was of 79.6% at both 5- (AUC: 0.804, 95%CI: 0.517-1.000) and 10-years (AUC: 0.804. 95%CI: 0.517-1.000) follow-up. In silico analysis of miR-210-3p and Docetaxel targets provided evidence for a putative molecular cross-talk involving microtubule regulation, drug efflux metabolism and oxidative stress response. Overall, our data point to the miR-210-3p involvement in the response to therapeutic regimens including Docetaxel in sequential therapy with anthracyclines, suggesting it may represent a predictive biomarker in breast cancer patients.

Authors+Show Affiliations

Fondazione IRCCS Casa Sollievo della Sofferenza Laboratorio di Oncologia, San Giovanni Rotondo, FG, Italy.Fondazione IRCCS Casa Sollievo della Sofferenza Laboratorio di Oncologia, San Giovanni Rotondo, FG, Italy.Fondazione IRCCS Casa Sollievo della Sofferenza Laboratorio di Oncologia, San Giovanni Rotondo, FG, Italy.Fondazione IRCCS Casa Sollievo della Sofferenza, UO di Biostatistica, San Giovanni Rotondo, FG, Italy.Fondazione IRCCS Casa Sollievo della Sofferenza, UO di Biostatistica, San Giovanni Rotondo, FG, Italy.Fondazione IRCCS Casa Sollievo della Sofferenza, Bioinformatics Unit, San Giovanni Rotondo, FG, Italy.Fondazione IRCCS Casa Sollievo della Sofferenza, UO di Oncologia, San Giovanni Rotondo, FG, Italy.Fondazione IRCCS Casa Sollievo della Sofferenza, UO di Oncologia, San Giovanni Rotondo, FG, Italy.Fondazione IRCCS Casa Sollievo della Sofferenza, UO di Oncologia, San Giovanni Rotondo, FG, Italy.Fondazione IRCCS Casa Sollievo della Sofferenza, UO di Anatomia Patologica, San Giovanni Rotondo, FG, Italy.Fondazione IRCCS Casa Sollievo della Sofferenza, UO di Chirurgia Senologica, San Giovanni Rotondo, FG, Italy.Fondazione IRCCS Casa Sollievo della Sofferenza Laboratorio di Oncologia, San Giovanni Rotondo, FG, Italy.Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain. Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain. Josep Carreras Leukaemia Research Institute, Badalona, Barcelona, Catalonia, Spain. Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Catalonia, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain.Fondazione IRCCS Casa Sollievo della Sofferenza Laboratorio di Oncologia, San Giovanni Rotondo, FG, Italy. pparrella@operapadrepio.it.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31624308

Citation

Pasculli, Barbara, et al. "Hsa-miR-210-3p Expression in Breast Cancer and Its Putative Association With Worse Outcome in Patients Treated With Docetaxel." Scientific Reports, vol. 9, no. 1, 2019, p. 14913.
Pasculli B, Barbano R, Rendina M, et al. Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel. Sci Rep. 2019;9(1):14913.
Pasculli, B., Barbano, R., Rendina, M., Fontana, A., Copetti, M., Mazza, T., ... Parrella, P. (2019). Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel. Scientific Reports, 9(1), p. 14913. doi:10.1038/s41598-019-51581-3.
Pasculli B, et al. Hsa-miR-210-3p Expression in Breast Cancer and Its Putative Association With Worse Outcome in Patients Treated With Docetaxel. Sci Rep. 2019 Oct 17;9(1):14913. PubMed PMID: 31624308.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel. AU - Pasculli,Barbara, AU - Barbano,Raffaela, AU - Rendina,Michelina, AU - Fontana,Andrea, AU - Copetti,Massimiliano, AU - Mazza,Tommaso, AU - Valori,Vanna Maria, AU - Morritti,Maria, AU - Maiello,Evaristo, AU - Graziano,Paolo, AU - Murgo,Roberto, AU - Fazio,Vito Michele, AU - Esteller,Manel, AU - Parrella,Paola, Y1 - 2019/10/17/ PY - 2019/02/21/received PY - 2019/10/04/accepted PY - 2019/10/19/entrez PY - 2019/10/19/pubmed PY - 2019/10/19/medline SP - 14913 EP - 14913 JF - Scientific reports JO - Sci Rep VL - 9 IS - 1 N2 - MicroRNA-210-3p is the most prominent hypoxia regulated microRNA, and it has been found significantly overexpressed in different human cancers. We performed the expression analysis of miR-210-3p in a retrospective cohort of breast cancer patients with a median follow-up of 76 months (n = 283). An association between higher levels of miR-210-3p and risk of disease progression (HR: 2.13, 95%CI: 1.33-3.39, P = 0.002) was found in the subgroup of patients treated with Epirubicin and Cyclophosphamide followed by Docetaxel. Moreover, a cut off value of 20.966 established by ROC curve analyses allowed to discriminate patients who developed distant metastases with an accuracy of 85% at 3- (AUC: 0.870, 95%CI: 0.690-1.000) and 83% at 5-years follow up (AUC: 0.832, 95%CI: 0.656-1.000). Whereas the accuracy in discriminating patients who died for the disease was of 79.6% at both 5- (AUC: 0.804, 95%CI: 0.517-1.000) and 10-years (AUC: 0.804. 95%CI: 0.517-1.000) follow-up. In silico analysis of miR-210-3p and Docetaxel targets provided evidence for a putative molecular cross-talk involving microtubule regulation, drug efflux metabolism and oxidative stress response. Overall, our data point to the miR-210-3p involvement in the response to therapeutic regimens including Docetaxel in sequential therapy with anthracyclines, suggesting it may represent a predictive biomarker in breast cancer patients. SN - 2045-2322 UR - https://www.unboundmedicine.com/medline/citation/31624308/Hsa-miR-210-3p_expression_in_breast_cancer_and_its_putative_association_with_worse_outcome_in_patients_treated_with_Docetaxel L2 - http://dx.doi.org/10.1038/s41598-019-51581-3 DB - PRIME DP - Unbound Medicine ER -